Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM)

• Status: Terminated
• Trial end date: 2011-05-01
• Target enrollment: 0
• Participant gender: All

Summary

To determine whether dasatinib plus lomustine are effective for treatment of recurrent glioblastoma

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Collaborator: European Organisation for Research and Treatment of Cancer - EORTC
• Treatments: Dasatinib; Lomustine

Criteria

Inclusion Criteria:

• Patients with histological or cytological proven glioblastoma multiforme

• Recurrent or progressive disease documented by magnetic resonance imaging (MRI)

• World Health Organization (WHO) Performance status 0 - 2

• Patient may have been operated for recurrence

• For non operated patients, recurrent disease must be at least one bidimensionally measurable target lesion with one diameter of at least 2cm

• Patients must be on a stable or decreasing dose of corticosteroids for at least 1 week prior to baseline MRI

Exclusion Criteria:

• Patients with histological or cytological proven glioblastoma multiforme

• Completion of radiotherapy to the brain less than 3 months prior to registration/randomization

• Prior treatment with high dose radiotherapy, stereotactic radiosurgery or internal radiation therapy

• Previous or current malignancy at other sites within prior 3 years